6.
Su P, Lee Y, Kuo L, Chen Y, Chen C, Kang Y
. Efficacy of AST-120 for Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2021; 12:676345.
PMC: 8350440.
DOI: 10.3389/fphar.2021.676345.
View
7.
Rapa S, Di Iorio B, Campiglia P, Heidland A, Marzocco S
. Inflammation and Oxidative Stress in Chronic Kidney Disease-Potential Therapeutic Role of Minerals, Vitamins and Plant-Derived Metabolites. Int J Mol Sci. 2020; 21(1).
PMC: 6981831.
DOI: 10.3390/ijms21010263.
View
8.
Prakash J, Hota J, Singh S, Sharma O
. Clinical spectrum of chronic renal failure in the elderly: a hospital based study from eastern India. Int Urol Nephrol. 2006; 38(3-4):821-7.
DOI: 10.1007/s11255-006-9003-y.
View
9.
Farr J, Fraser D, Wang H, Jaehn K, Ogrodnik M, Weivoda M
. Identification of Senescent Cells in the Bone Microenvironment. J Bone Miner Res. 2016; 31(11):1920-1929.
PMC: 5289710.
DOI: 10.1002/jbmr.2892.
View
10.
Fusaro M, Barbuto S, Gallieni M, Cossettini A, Re Sarto G, Cosmai L
. Real-world usage of Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices. Clin Kidney J. 2024; 17(1):sfad290.
PMC: 10784916.
DOI: 10.1093/ckj/sfad290.
View
11.
Liu W, Wu C, Lim P, Chien S, Hou Y, Zheng C
. Effect of uremic toxin-indoxyl sulfate on the skeletal system. Clin Chim Acta. 2018; 484:197-206.
DOI: 10.1016/j.cca.2018.05.057.
View
12.
Chang J, Kuo H, Liu S, Hsieh C, Hsu C, Hung K
. Translational Medicine in Uremic Vascular Calcification: Scavenging ROS Attenuates p-Cresyl Sulfate-Activated Caspase-1, NLRP3 Inflammasome and Eicosanoid Inflammation in Human Arterial Smooth Muscle Cells. Life (Basel). 2022; 12(5).
PMC: 9147867.
DOI: 10.3390/life12050769.
View
13.
Zhang S, Xu J, Si H, Wu Y, Zhou S, Shen B
. The Role Played by Ferroptosis in Osteoarthritis: Evidence Based on Iron Dyshomeostasis and Lipid Peroxidation. Antioxidants (Basel). 2022; 11(9).
PMC: 9495695.
DOI: 10.3390/antiox11091668.
View
14.
Aoki C, Uto K, Honda K, Kato Y, Oda H
. Advanced glycation end products suppress lysyl oxidase and induce bone collagen degradation in a rat model of renal osteodystrophy. Lab Invest. 2013; 93(11):1170-83.
DOI: 10.1038/labinvest.2013.105.
View
15.
Yamamoto S, Fukagawa M
. Uremic Toxicity and Bone in CKD. J Nephrol. 2017; 30(5):623-627.
DOI: 10.1007/s40620-017-0406-x.
View
16.
Wang H, Liu X, Yang H, Jing X, Wang W, Liu X
. Activation of the Nrf-2 pathway by pinocembrin safeguards vertebral endplate chondrocytes against apoptosis and degeneration caused by oxidative stress. Life Sci. 2023; 333:122162.
DOI: 10.1016/j.lfs.2023.122162.
View
17.
Ghosh B, Brojen T, Banerjee S, Singh N, Singh S, Sharma O
. The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study. Indian J Nephrol. 2012; 22(4):285-91.
PMC: 3495351.
DOI: 10.4103/0971-4065.101249.
View
18.
Zhou X, Zheng Y, Sun W, Zhang Z, Liu J, Yang W
. D-mannose alleviates osteoarthritis progression by inhibiting chondrocyte ferroptosis in a HIF-2α-dependent manner. Cell Prolif. 2021; 54(11):e13134.
PMC: 8560605.
DOI: 10.1111/cpr.13134.
View
19.
Mosinska P, Storr M, Fichna J
. The role of AST-120 and protein-bound uremic toxins in irritable bowel syndrome: a therapeutic perspective. Therap Adv Gastroenterol. 2015; 8(5):278-84.
PMC: 4530433.
DOI: 10.1177/1756283X15587866.
View
20.
Shanahan C, Crouthamel M, Kapustin A, Giachelli C
. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011; 109(6):697-711.
PMC: 3249146.
DOI: 10.1161/CIRCRESAHA.110.234914.
View